Covid-19 News

Patron saint of pandemics being called out!

Rand Paul: Fauci sees himself as 'Greek philosopher' whose 'lies are noble lies'

Biden chief medical adviser feels 'Americans aren't smart enough to make informed decisions,' Paul tells Laura Ingraham

https://news.google.com/articl…=en-US&gl=US&ceid=US%3Aen

White House chief medical adviser Dr. Anthony Fauci appears to view himself as a "Greek philosopher" who tells "noble lies" to help the public, Sen. Rand Paul, R-Ky., told "The Ingraham Angle" Friday.

"He's not telling you this because he's a mean man," Paul told host Laura Ingraham. "He's telling you this because he feels sorry for you, because you don't understand and Americans aren't smart enough to make informed decisions."

The most obvious example of this, Paul added, is Fauci's statement in the early months of the pandemic that Americans should not wear masks because they would do nothing to stop the spread of the virus.

Later on, he said all masks do work," the senator stated, "but that is a lie also because really only the N95 masks work. It is a compilation of lies, but they're all done to protect you because he doesn't think you are smart enough to make any of these decisions on your own."

While discussing the effectiveness of lockdowns and other coronavirus restrictions, Paul said he hoped the issue would be studied "in an objective way."

You can sequentially look at the date when each mandate was passed and when it got ratcheted up. You can look at the incidence of the disease, and what you find is they were proportional, meaning the more mandates we got, the more disease we got.

"The mandates did not cause the disease but there is no evidence the mandate slowed down the disease at all," said Paul.

Research still is not connecting the dots. Vitamn deficenccy renders most monoclonal treatments useless. Memory t and b cells are regulated by vitamn d.

Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike

https://www.biorxiv.org/conten…/2021.03.10.434840v1.full

ABSTRACT

Memory B cell reserves can generate protective antibodies against repeated SARS-CoV-2 infections, but with an unknown reach from original infection to antigenically drifted variants. We charted memory B cell receptor-encoded monoclonal antibodies (mAbs) from 19 COVID-19 convalescent subjects against SARS-CoV-2 spike (S) and found 7 major mAb competition groups against epitopes recurrently targeted across individuals. Inclusion of published and newly determined structures of mAb-S complexes identified corresponding epitopic regions. Group assignment correlated with cross-CoV-reactivity breadth, neutralization potency, and convergent antibody signatures. mAbs that competed for binding the original S isolate bound differentially to S variants, suggesting the protective importance of otherwise-redundant recognition. The results furnish a global atlas of the S-specific memory B cell repertoire and illustrate properties conferring robustness against emerging SARS-CoV-2 variants.

RESULTS

Monoclonal antibody (mAb) isolation

To identify the general pattern of SARS-CoV-2 S recognition by memory B cells in convalescent subjects, we sorted single CD19+ CD27+ IgG+ B cells recognizing soluble prefusion-stabilized S trimer (Fig. 1A, Fig. S1) from 19 individuals with a history of COVID-19 (Data S1). Because less is known about S-reactive antibodies that bind outside the RBD region, we also sorted S-reactive B cells that did not bind RBD from 3 individuals. S-reactive B cells made up 0.2% (0.07%-0.4%) of the total B cell population (Fig. 1A left panel), with RBD-binding cells representing about a quarter of S-reactive IgG+ B cells (Fig. 1A right panel) consistent with prior work (18).

this may seem off subject but could lead to treating long Covid

NE Journal of Medicine publishes study on Alzheimer’s treatment with promising results

https://www.boston.com/news/he…d-journal-of-medicine/amp

The U.S. Food and Drug Administration hasn’t approved a new medication for Alzheimer’s since 2003, but a new study published by the New England Journal of Medicine on Saturday is showing hopeful initial results.

Donanemab, an antibody treatment produced by drug-maker Eli Lilly and Company, targets a modified form of amyloid-β (Aβ) peptide — a plaque that accumulates in the brains of people with Alzheimer’s. Early-stage clinical trial results showed that by 52 weeks in, the amyloid plaque levels of those receiving the experimental drug achieved a negative status. In other words, their amyloid plaque levels were the same as the average person’s.

To set the study up, half of the 275 participating patients received the drug for 76 weeks as part of the trial, while the other half received a placebo. Those involved were people with early symptomatic Alzheimer’s disease.

“We are confident in the results of the TRAILBLAZER-ALZ study,” Daniel Skovronsky, Lilly’s chief scientific officer and president of Lilly Research Laboratories, said in a statement. “This is the first late-stage study in Alzheimer’s disease to meet its primary endpoint at the primary analysis. Donanemab has the potential to become a very important treatment for Alzheimer’s disease.”

By monitoring memory and the ability to perform daily tasks, researchers also discovered that the drug seems to slow cognitive decline by about 32%.

Overall, about 40% of participants treated with donanemab achieved amyloid negativity as early as six months after starting treatment, and 68% reached this goal by 18 months in.

“We were pleased to see not only slowing of cognitive and functional decline, but also very substantial clearance of amyloid plaques and slowing of spread of tau pathology,” Skovronsky said. “The constellation of clinical and biomarker results indicates the potential for long-term disease modification. We are grateful to the patients, caregivers, and investigators who participated in this landmark study.”

Though results are promising, researchers said longer and more expansive trials are still necessary going forward to ensure donanemab’s safety.

According to the Centers for Disease Control and Prevention, Alzheimer’s is one of the top 10 leading causes of death in the U.S., and the fifth leading cause of death among adults aged 65 or older.

The FDA is also currently undergoing a review of another, separate experimental drug from Biogen, a Cambridge-based company, and Japanese partner Eisai Co.

Only a handful of drugs are approved to manage Alzheimer’s symptoms, and there are none to treat the cause.

This study related to this study

Cognitive impact of COVID-19: looking beyond the short term

https://alzres.biomedcentral.c…0.1186/s13195-020-00744-w

Abstract

COVID-19 is primarily a respiratory disease but up to two thirds of hospitalised patients show evidence of central nervous system (CNS) damage, predominantly ischaemic, in some cases haemorrhagic and occasionally encephalitic. It is unclear how much of the ischaemic damage is mediated by direct or inflammatory effects of virus on the CNS vasculature and how much is secondary to extracranial cardiorespiratory disease. Limited data suggest that the causative SARS-CoV-2 virus may enter the CNS via the nasal mucosa and olfactory fibres, or by haematogenous spread, and is capable of infecting endothelial cells, pericytes and probably neurons. Extracranially, SARS-CoV-2 targets endothelial cells and pericytes, causing endothelial cell dysfunction, vascular leakage and immune activation, sometimes leading to disseminated intravascular coagulation. It remains to be confirmed whether endothelial cells and pericytes in the cerebral vasculature are similarly targeted. Several aspects of COVID-19 are likely to impact on cognition. Cerebral white matter is particularly vulnerable to ischaemic damage in COVID-19 and is also critically important for cognitive function. There is accumulating evidence that cerebral hypoperfusion accelerates amyloid-β (Aβ) accumulation and is linked to tau and TDP-43 pathology, and by inducing phosphorylation of α-synuclein at serine-129, ischaemia may also increase the risk of development of Lewy body disease. Current therapies for COVID-19 are understandably focused on supporting respiratory function, preventing thrombosis and reducing immune activation. Since angiotensin-converting enzyme (ACE)-2 is a receptor for SARS-CoV-2, and ACE inhibitors and angiotensin receptor blockers are predicted to increase ACE-2 expression, it was initially feared that their use might exacerbate COVID-19. Recent meta-analyses have instead suggested that these medications are protective. This is perhaps because SARS-CoV-2 entry may deplete ACE-2, tipping the balance towards angiotensin II-ACE-1-mediated classical RAS activation: exacerbating hypoperfusion and promoting inflammation. It may be relevant that APOE ε4 individuals, who seem to be at increased risk of COVID-19, also have lowest ACE-2 activity. COVID-19 is likely to leave an unexpected legacy of long-term neurological complications in a significant number of survivors. Cognitive follow-up of COVID-19 patients will be important, especially in patients who develop cerebrovascular and neurological complications during the acute illness.

Quote from Fm1

White House chief medical adviser Dr. Anthony Fauci

Why discussing about Dr. Mengele?? He is directly responsible for 500'000 dead Americans because he organized & financed the Wuhan gain-off corona research and blocks Ivermectin!

Why is he still in power and not in jail? Because daddy Biden has to ensure this years net gain of Pfizer first ?

Not so good news... after seven reported cases of problems with blood clots in brain veins (out of 1,7 million vaccinations in total) Germany has temporary suspended vaccinations with Astrazeneca.... until further clarification by the company. Meanwhile all other EU countries did follow...

https://apnews.com/article/bus…e13370c96c873e896387eb92f

More info for the deniers and liers

Ivermectin works and the FDA is criminal!!!

Germany, France Italy suspend AstraZeneca vaccinations; safety agency says blood clot incidence is low

https://www.washingtonpost.com…pdates-us/?outputType=amp

Germany became the world’s largest country to suspend the use of AstraZeneca’s coronavirus vaccine Monday, following reports of blood clots in people who were inoculated. Germany’s health ministry described the measure as “precautionary.”

The decision followed the detection of seven cases of blood clots in the brain, out of 1.6 million people who have received the vaccine in the country, Health Minister Jens Spahn said in a news conference.

France and Italy also announced Monday that they would suspend the use of the vaccine out of an abundance of caution while awaiting an analysis from the European Medicines Agency, which is expected to be finalized this week.

Drugmaker AstraZeneca said late Sunday that there is no scientific evidence of any link between its coronavirus vaccine and recent deaths in Europe from blood clots. The rate of blood clots in people who have been inoculated with the vaccine is “much lower than would be expected to occur naturally in a general population,” the company said in a statement.

“We are all aware of the far-reaching consequences of this decision,” Spahn said of the halt. German health authorities recommended that anyone who has not felt well for more than four days after receiving the jab to seek medical advice.

The vaccine, developed alongside Britain’s Oxford University, has yet to be approved in the United States and has struggled to build confidence around its product in Europe. Its trial data was criticized, while several European countries did not initially approve it for use among people over 65.

The World Health Organization and European regulators have continued to express confidence in its safety. Spahn said European regulators would now have to decide whether new information would impact the vaccine’s authorization.

Quote from Fm1

Ivermectin works and the FDA is criminal!!!

The mafia obviously controls all journals. So Lancet now is a paper run by criminals that for profit reasons did decide not to publish the Ivermectin summary study.

It's all about delaying the help from Ivermectin to make 10000x moire money with dirt - this includes the untested vaccines! So after CoV-19 the world has to live with a totally damaged medical system. Nobody ever will trust in anything lancet publishes expect mafia doctors.

Quote from zorud

Meanwhile all other EU countries did follow...

Not true! Austria has not yet suspended the use of the ASZ vaccine, despite some obvious issues. We are waiting on further info from EMA.

One reason is we just bought too much of it. An additional issue is the unbalanced distribution of vaccines in Europe, since every member country has to pay the invoice. Poorer countries are left in the rain and have to look for other alternatives like ivermectin. E.g. Bulgaria which is actually nice to see.

This makes it more difficult for Big pharma to hide the truth about IVM.

Why the Pandemic Experts Failed

We're still thinking about pandemic data in the wrong ways.

https://amp.theatlantic.com/amp/article/618287/

After spending a year building one of the only U.S. pandemic-data sources, we have come to see the government’s initial failure here as the fault on which the entire catastrophe pivots. The government has made progress since May; it is finally able to track pandemic data. Yet some underlying failures remain unfixed. The same calamity could happen again.

UK Clinical Trial Confirms SaNOtize’s Breakthrough Treatment for COVID-19

https://www.businesswire.com/n…gh-Treatment-for-COVID-19

VANCOUVER, British Columbia & SURREY, England--(BUSINESS WIRE)--Biotech company SaNOtize Research & Development Corp., (SaNOtize), Ashford and St Peter’s Hospitals NHS Foundation Trust in Surrey, UK, and Berkshire and Surrey Pathology Services, UK, today announced results of clinical trials indicating that SaNOtize’s Nitric Oxide Nasal Spray (NONS) represents a safe and effective antiviral treatment that could prevent the transmission of COVID-19, shorten its course, and reduce the severity of symptoms and damage in those already infected.

Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial -- Details

This study, conducted by Dr Stephen Winchester and Dr Isaac John at Ashford and St. Peter’s Hospitals NHS Foundation Trust, was devised to determine the clinical efficacy of NONS for the treatment of mild COVID-19 infection. The primary outcome measure was the difference in SARS-CoV-2 RNA load from baseline through Day 6 between NONS and control arms.

“NONS destroys the virus, blocks entry into and halts viral replication within the nasal cavity, which rapidly reduces viral load. This is significant because viral load has been linked to infectivity and poor outcomes,” said Dr. Chris Miller, Chief Science Officer and co-founder of SaNOtize. “There is currently a lack of an antiviral therapy that is effective against COVID-19 and its variants, can prevent or shorten the course of the disease, reduce damage, lower the severity of COVID-19, and can be made widely and readily available to the public. This is what makes NONS unique and enables it to stand alone from any other novel therapeutic application.”

The study concluded that NONS accelerated clearance of SARS-CoV-2 by a factor of 16-fold versus the placebo, and it presents supporting evidence for the emergency use of NONS for prevention or treatment of patients with recent or established SARS-CoV-2 RNA infection during this COVID-19 pandemic.

“The rigour of this trial and the decades of safety data behind nitric oxide gives us full confidence in requesting emergency use approval in the UK, Canada and elsewhere in the world.” said Rob Wilson, SaNOtize’s UK representative. “We are pleased to have conducted this crucial trial in the NHS and now hope that regulators will play their part in arming the public in the battle against this devastating disease.”

Quote from Fm1

VANCOUVER, British Columbia & SURREY, England--(BUSINESS WIRE)--Biotech company SaNOtize Research & Development Corp., (SaNOtize), Ashford and St Peter’s Hospitals NHS Foundation Trust in Surrey, UK, and Berkshire and Surrey Pathology Services, UK, today announced results of clinical trials indicating that SaNOtize’s Nitric Oxide Nasal Spray (NONS) represents a safe and effective antiviral treatment that could prevent the transmission of COVID-19, shorten its course, and reduce the severity of symptoms and damage in those already infected.

Recall an old post about the counterintuitive (seeming) reduction in Covid among smokers.

Smoke contains nitric oxide.

From https://pubmed.ncbi.nlm.nih.gov/12215243/

Smokers are exposed first to high concentrations of inhaled NO from smoke and, second, to endogenously released NO after uptake of nicotine into the brain. As a result, the basal endogenous NO synthesis in airways and blood vessels of smokers is reduced.

Perhaps Alan's year-ago(?) whimsical smoke 'fumigation' proposal wasn't far from the truth.

Also, recall a fairly recent post that humming greatly increases the nitric oxide produced endogenously by the cells of the nasal cavity surface. This is maximized with a hum at a frequency at C2, the C note an octave below middle C. (Unluckily, most women can't reach down to C2 ! ). There are reports of humming being very effective at reducing sinus infection trouble.

Quote from Mark U

Smokers are exposed first to high concentrations of inhaled NO]

Smokers in some nursing homes have been shown unexpectedly to have less viral infections

Smokers tend to have higher Vit D levels . because they are forced to spend more time ,20-30 min n the sun..

..

Quote from RobertBryant

..

A proposed study of nicotine patch. Results shortly

https://clinicaltrials.gov/ct2/show/NCT04608201

Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Hospitalized Patients (NICOVID)

Brief Summary:

The coronavirus disease (COVID-19) epidemic represents a major therapeutic challenge. The highly contagious severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) and the long duration of the disease have led to a massive influx of patients admitted in health services and intensive care units. To current knowledge, there is no treatment yet that that can prevent infection from SARS-COV-2 virus, nor the disease progression to a severe form.

Daily active smokers are rare among outpatients or hospitalized COVID-19 patients.

Several arguments suggest that nicotine could be responsible for this protective effect thank to the nicotinic acetylcholine receptor (nAChR).

Based on epidemiological data and experimental data from scientific literature, we hypothesize that nicotine could inhibit the penetration and spread of the virus and improve the management of COVID19 , particularly in hospitalized patients to prevent adverse outcomes (death, transfer to intensive care unit, care limitation, mechanical ventilation an high flow oxygen

here is your reason for no early treatment

Here's what Covid vaccines are worth to Big Pharma

https://amp.cnn.com/cnn/2021/0…-covid-vaccine/index.html

New York(CNN Business)The various Covid-19 vaccines currently being distributed around the globe have the potential to end the worst pandemic in a century. They also will mean hundreds of billions dollars in sales for the pharmaceutical companies that make them.

Despite being priced at less than $20 per dose, Pfizer (PFE) expects sales of the vaccine it developed with BioNTech (BNTX) to total about $15 billion by the end of this year, with a profit margin of nearly 30%.

Vaccines are typically not the most profitable products in the Big Pharma catalog, especially compared to drugs used to treat chronic conditions.

"Flu vaccines on balance are a lower margin business," said Seamus Fernandez, senior managing director at Guggenheim Securities. There are of course exceptions — including the Prevnar vaccine that protects the elderly from pneumococcal pneumonia, which Fernandez describes as "extremely lucrative" for Pfizer. And the drug maker's Covid vaccine is likely to be an even a bigger money maker.

Developing the vaccines was a gamble for the all the companies that tried, even with most drug makers accepting government grands.

"It would have been a terrible business if the vaccine had failed. It would have been a write off," Fernandez said. "Obviously for Pfizer and Moderna (MRNA) and Johnson & Johnson, it succeeded pretty spectacularly."

Although Johnson & Johnson (JNJ) has said it will provide the vaccine on a not-for-profit basis as long as the world continues suffering from the pandemic, that doesn't mean the company won't ever make money from it.

That's because there is an assumption among experts and executives at the drug companies that, even after the pandemic has passed, people will need to receive booster shots to protect themselves from new variants.

"Genetic mutations occur naturally during virus replication and spread," Pfizer CEO Albert Bourla said in his most recent call with analysts. "There is an increasingly probable scenario when it could become necessary within the next few years to boost COVID-19 vaccinated patients with a vaccine encoding the spike variant."

That will mean even more sales — and more profits — from the vaccine

Quote from Fm1

Developing the vaccines was a gamble for the all the companies that tried, even with most drug makers accepting government grands.

It was no gamble at all. Germany paid about 500mio$ for the development the USA about the same. Real gambling with state - taxpayers money.

Now Switzerland ordered > 20 mio. dose for about 1/3 of the population (3 mio.) that is willing to engage in a human trial....

Quote from gerold.s

Not true! Austria has not yet suspended the use of the ASZ vaccine, despite some obvious issues. We are waiting on further info from EMA.

One reason is we just bought too much of it. An additional issue is the unbalanced distribution of vaccines in Europe, since every member country has to pay the invoice. Poorer countries are left in the rain and have to look for other alternatives like ivermectin. E.g. Bulgaria which is actually nice to see.

This makes it more difficult for Big pharma to hide the truth about IVM.

Meanwhile more countries put a hold onto the Astrazeneca vaccinations... In Germany there was a clear link of these severe side effects to the vaccination: 7 vein tromboses (3 deaths unfortunately) occured within a population of 1.6 million vaccinated people younger than 50 years (6 women, 1 man) - the "normal" occurance is one (!) in a comparable cohort without vaccination. Another important factor for the temporary suspension was a legal fact: knowing, this severe side effects may be linked to the vaccination, would open the door for law suits of affected patients, if the vaccination would go on...

yes, why should anyone question vaccines and safety?

Pfizer's COVID-19 vaccine faced EMA manufacturing concerns ahead of emergency nod: report

https://www.fiercepharma.com/m…g-concerns-ahead-december

About a month before Pfizer and BioNTech won an emergency nod for their COVID-19 vaccine in Europe, regulators raised flags about lower-than-expected levels of intact mRNA in commercial batches, the BMJ reports.

The European Medicines Agency outlined “a significant difference" in the RNA in clinical batches and the proposed commercial batches, according to information leaked from an EMA cyberattack in December, which the BMJ subsequently reviewed.

While the production issue has since been resolved—and Pfizer's vaccine has since won approval in Europe—the leaks show the “complexities of quality assurance” for mRNA vaccines, especially with regards to RNA instability, the BMJ said. It’s an issue that affects all mRNA developers, including Moderna and CureVac. That instability is the reason for the shots’ frigid cold chain requirements and the need to encapsulate mRNA in lipid nanoparticles, BMJ said.

And now let's throw politics into it

Suspension of AstraZeneca shots is 'political decision': Italy's medicines regulator head

https://mobile.reuters.com/article/amp/idUSKBN2B80KK

(Reuters) - The decision by Germany, France and Italy to suspend AstraZeneca's COVID-19 shots after several countries reported possible serious side-effects is a "political one", the director general of Italy's medicines authority AIFA said on Tuesday.

"We got to the point of a suspension because several European countries, including Germany and France, preferred to interrupt vaccinations... to put them on hold in order to carry out checks. The choice is a political one," Nicola Magrini told daily la Repubblica in an interview.

And topping that off...... The EU is upset with italy for it's agreement to manufacture Sputnik vaccine.

And I thought it was about ending the pandemic but now governments just want to make a buck off of misery.

Unfortunately, blood clots seem to be a "common" severe side effect - althouhg a very rare one - among ALL currently used Corona vaccines...?? May need deeper investigation, in order not to mix those side effetcs known caused by Covid anyway...

https://www.express.co.uk/life…ine-cause-blood-clots-EVG

FLCCC update